scispace - formally typeset
E

Eyal Gottlieb

Researcher at Technion – Israel Institute of Technology

Publications -  159
Citations -  33370

Eyal Gottlieb is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Mitochondrion & Cancer. The author has an hindex of 67, co-authored 140 publications receiving 26228 citations. Previous affiliations of Eyal Gottlieb include University of Pennsylvania & Rappaport Faculty of Medicine.

Papers
More filters
Journal ArticleDOI

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Lorenzo Galluzzi, +186 more
TL;DR: The Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives.
Journal ArticleDOI

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

TL;DR: A functional classification of cell death subroutines is proposed that applies to both in vitro and in vivo settings and includes extrinsic apoptosis, caspase-dependent or -independent intrinsic programmed cell death, regulated necrosis, autophagic cell death and mitotic catastrophe.
Journal ArticleDOI

TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis

TL;DR: expression of TIGAR may modulate the apoptotic response to p53, allowing survival in the face of mild or transient stress signals that may be reversed or repaired, and the decrease of intracellular ROS levels in response to TIGar may also play a role in the ability of p53 to protect from the accumulation of genomic damage.
Journal ArticleDOI

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase

TL;DR: A mitochondrion-to-cytosol signaling pathway that links mitochondrial dysfunction to oncogenic events is described, suggesting a mechanistic link between SDH mutations and HIF-1alpha induction, providing an explanation for the highly vascular tumors that develop in the absence of VHL mutations.